| 2023-09 |
Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features |
Diagnostics
|
| 2023-09 |
Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer |
Journal of the National Cancer Institute
|
| 2023-04 |
Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA |
Nature communications
|
| 2023-01 |
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates |
Breast Cancer Research
|
| 2023-01 |
Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea |
Palliative Medicine Reports
|
| 2023-01 |
Anaemia and pathologic complete response rate according to carboplatin dose in HER2+breast cancer treated with neoadjuvant TCHP |
CANCER MEDICINE
|
| 2022-10 |
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant (vol 28, pg 1500, 2022) |
CLINICAL CANCER RESEARCH
|
| 2022-09 |
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer The Neo-PATH Phase 2 Nonrandomized Clinical Trial |
JAMA ONCOLOGY
|
| 2022-08 |
Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts |
International Journal of Molecular Sciences
|
| 2022-07 |
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
New England Journal of Medicine
|
| 2022-05 |
Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer |
Cancers
|
| 2022-04 |
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial |
Annals of Oncology
|
| 2021-12 |
Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study) |
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
|
| 2021-11 |
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2(-)-Advanced Breast Cancer |
CLINICAL CANCER RESEARCH
|
| 2021-10 |
Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline <i>BRCA1/2</i> Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial |
CANCER RESEARCH AND TREATMENT
|
| 2021-10 |
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11) |
ESMO OPEN
|
| 2021-10 |
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer |
Pharmaceuticals
|
| 2021-10 |
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations |
INVESTIGATIONAL NEW DRUGS
|
| 2021-08 |
Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib |
JCO PRECISION ONCOLOGY
|
| 2021-07 |
Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective |
ANNALS OF SURGERY
|
| 2021-06 |
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups |
NPJ BREAST CANCER
|
| 2021-06 |
Increased resting‑state cerebellar‑cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy |
SCIENTIFIC REPORTS
|
| 2021-06 |
Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer |
FRONTIERS IN ONCOLOGY
|
| 2021-05 |
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis |
ANNALS OF ONCOLOGY
|
| 2021-04 |
Genomic landscape of extraordinary responses in metastatic breast cancer |
COMMUNICATIONS BIOLOGY
|
| 2021-02 |
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study |
EUROPEAN JOURNAL OF CANCER
|
| 2021-01 |
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer |
CLINICAL CANCER RESEARCH
|
| 2020-12 |
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) |
JOURNAL OF CLINICAL ONCOLOGY
|
| 2020-08 |
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer |
BREAST CANCER RESEARCH AND TREATMENT
|
| 2020-08 |
Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis |
BREAST CARE
|
| 2020-07 |
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting |
CANCER RESEARCH AND TREATMENT
|
| 2020-05 |
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study |
ANNALS OF ONCOLOGY
|
| 2020-05 |
Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potentialtreatment for triple-negative breast cancer |
EXPERIMENTAL AND MOLECULAR MEDICINE
|
| 2020-02 |
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older |
BREAST CANCER RESEARCH AND TREATMENT
|
| 2019-12 |
Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models |
PLOS ONE
|
| 2019-09 |
Effect of primary tumor resection on overall survival in patients with stage IV breast cancer. |
BREAST JOURNAL
|
| 2019-04 |
A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide. |
CANCER RESEARCH AND TREATMENT
|
| 2019-02 |
차세대 염기서열 분석법과 항암요법 |
Journal of the Korean Medical Association(대한의사협회지)
|
| 2019-01 |
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01) |
CANCER RESEARCH AND TREATMENT
|
| 2018-11 |
Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer |
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
|
| 2018-07 |
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. |
Journal of Global Oncology
|
| 2018-07 |
Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients |
CANCER RESEARCH AND TREATMENT
|
| 2018-06 |
External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence |
Radiation Oncology Journal
|
| 2018-04 |
Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective |
CLINICAL BREAST CANCER
|
| 2018-03 |
The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. |
CANCER NURSING
|
| 2018-01 |
CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator |
ONCOTARGET
|
| 2017-09 |
Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea |
JOURNAL OF BREAST CANCER
|
| 2017-09 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study |
EUROPEAN JOURNAL OF CANCER
|
| 2017-07 |
An Open-label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer |
CANCER RESEARCH AND TREATMENT
|
| 2017-06 |
Chemotherapy-induced irreversible alopecia in early breast cancer patients |
BREAST CANCER RESEARCH AND TREATMENT
|
| 2017-06 |
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer |
BREAST CANCER RESEARCH AND TREATMENT
|
| 2017-05 |
Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results |
ANNALS OF SURGICAL TREATMENT AND RESEARCH
|
| 2017-04 |
Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer. |
PLOS ONE
|
| 2017-01 |
Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR |
YONSEI MEDICAL JOURNAL
|
| 2016-10 |
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study |
CANCER RESEARCH AND TREATMENT
|
| 2016-04 |
The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer |
PLOS ONE
|
| 2016-03 |
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy |
JOURNAL OF BREAST CANCER
|
| 2016-03 |
Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer |
ONCOTARGET
|
| 2016-02 |
Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer |
PLOS ONE
|
| 2015-10 |
Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay |
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
|
| 2015-08 |
Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence? |
MEDICINE
|
| 2015-06 |
Prediction of short- and long-term survival for advanced cancer patients after ICU admission |
SUPPORTIVE CARE IN CANCER
|
| 2015-03 |
성장인자수용체-2 양성 유방암 조직에서 표적치료 전후의 성장인자수용체군 발현양상 |
Korean Journal of clinical oncology (대한임상종양학회지)
|
| 2015-03 |
Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): Prevalence, clinicopathologic features and prognostic implication |
PLOS ONE
|
| 2014-10 |
cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer |
JOURNAL OF CANCER
|
| 2014-03 |
Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer |
CANCER
|
| 2013-12 |
Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer |
BREAST
|
| 2013-12 |
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: Phase II trial |
BMC CANCER
|
| 2013-10 |
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer |
INVESTIGATIONAL NEW DRUGS
|